300723.SZ
一品红
SZSE · Healthcare · C 制造业 · CN
CNY 34.61
−5.82%Sep 3, 2026, 09:38 UTC
Yipinhong announced that its gout innovative drug AR882 (deupirtenone) capsules met the primary endpoint in a Phase III clinical trial for treating gout with hyperuricemia, showing significant efficacy and good safety.
Source:Aug 21, 2026, 03:44 UTC
Yipinhong's wholly-owned subsidiary Guangzhou Yipinhong Pharmaceutical received approval from China's National Medical Products Administration to conduct clinical trials for its self-developed innovative drug APH03867 tablets, intended for treating gout with hyperuricemia.
Source:Aug 17, 2026, 09:48 UTC
Yipinhong's subsidiary Guangzhou Yipinhong Pharmaceutical received approval from China's National Medical Products Administration to conduct clinical trials for its innovative drug APH04935, a small-molecule GLP-1R agonist for weight control.
Source: